Immunic to Participate in Investor and Scientific Conferences in February
NEW YORK, Feb. 1, 2024 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:
Related news for (IMUX)
- Immunic to Participate in Scientific and Investor Conferences in October
- Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
- Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dose Strengths in Progressive Multiple Sclerosis
- Immunic to Participate in Investor and Scientific Conferences in September
- Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update